Knowledge Graphs (KGs) are foundational structures in many AI applications, representing entities and their interrelations through triples. However, triple-based KGs lack the contextual information of relational knowledge, like temporal dynamics and provenance details, which are crucial for comprehensive knowledge representation and effective reasoning. Instead, \textbf{Context Graphs} (CGs) expand upon the conventional structure by incorporating additional information such as time validity, geographic location, and source provenance. This integration provides a more nuanced and accurate understanding of knowledge, enabling KGs to offer richer insights and support more sophisticated reasoning processes. In this work, we first discuss the inherent limitations of triple-based KGs and introduce the concept of CGs, highlighting their advantages in knowledge representation and reasoning. We then present a context graph reasoning \textbf{CGR$^3$} paradigm that leverages large language models (LLMs) to retrieve candidate entities and related contexts, rank them based on the retrieved information, and reason whether sufficient information has been obtained to answer a query. Our experimental results demonstrate that CGR$^3$ significantly improves performance on KG completion (KGC) and KG question answering (KGQA) tasks, validating the effectiveness of incorporating contextual information on KG representation and reasoning.

Humans make numerous inferences in text comprehension to understand discourse. This paper aims to understand the commonalities and disparities in the inference judgments between humans and state-of-the-art Large Language Models (LLMs). Leveraging a comprehensively curated entailment verification benchmark, we evaluate both human and LLM performance across various reasoning categories. Our benchmark includes datasets from three categories (NLI, contextual QA, and rationales) that include multi-sentence premises and different knowledge types, thereby evaluating the inference capabilities in complex reasoning instances. Notably, our findings reveal LLMs' superiority in multi-hop reasoning across extended contexts, while humans excel in tasks necessitating simple deductive reasoning. Leveraging these insights, we introduce a fine-tuned Flan-T5 model that outperforms GPT-3.5 and rivals with GPT-4, offering a robust open-source solution for entailment verification. As a practical application, we showcase the efficacy of our finetuned model in enhancing self-consistency in model-generated explanations, resulting in a 6% performance boost on average across three multiple-choice question-answering datasets.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. COVID: Artificial intelligence-generated COVID drug enters clinical trials. WORK TOGETHER: Embracing AI means we must mitigate risk to firms, industries, consumers and society. TERRIFYING TECH: Criminal enterprise flaunts AI in creepy commercial meant for dark web.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. Artificial intelligence is increasingly moving into the health care arena and helping to streamline medical processes -- including the creation of new drugs. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials. This oral drug is a treatment, not a vaccine.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. In humanity's quest to live longer, healthier lives, technology -- particularly artificial intelligence -- is playing an ever-bigger role and expanding into more areas of health care. A California-based medical technology company named Prenuvo, for instance, offers full-body MRI scans that leverage AI to screen patients for over 500 conditions -- including tumors, aneurysms and cysts -- in less than an hour. Now, Prenuvo is announcing a partnership with Cenegenics, a Las Vegas-based company that offers "personalized performance health age management" for its patients.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. AI experts and tech-inclined political scientists are sounding the alarm on the unregulated use of AI tools going into an election season. Generative AI can not only rapidly produce targeted campaign emails, texts or videos, it also could be used to mislead voters, impersonate candidates and undermine elections on a scale and at a speed not yet seen. A booth is ready for a voter, Feb. 24, 2020, at City Hall in Cambridge, Mass., on the first morning of early voting in the state.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. Imagine a world where "interspecies communication" isn't the stuff of sci-fi fantasies - instead, a reality where humans can chit-chat with their furry, feathery, and scaly friends. This is where AI swoops in like a superhero, with researchers using algorithms to decipher animal vocalizations, movements, and even facial expressions. The Earth Species Project, a non-profit organization dedicated to decoding animal communication, is at the forefront of this groundbreaking research.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. The accessibility of artificial intelligence (AI) will change the international landscape to empower "bad actor" strongman regimes and lead to unprecedented social disruptions, a risk analysis expert told Fox News Digital. "We know that when you have a bad actor, and all they have is a single-shot rifle as opposed to an AR-15, they can't kill as many people, and the AR-15 is nothing compared to what we are going to see from artificial intelligence, from the disruptive uses of these tools," said Ian Bremmer, founder and president of political risk research firm Eurasia Group. In referencing improved capabilities for autonomous drones and the ability to develop new viruses, among others, Bremmer said that "we've never seen this level of malevolent power that will be in the hands of bad actors."

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. Artificial intelligence already has a lengthy track record in the field of weather prediction, where it has helped prognosticators make faster, more accurate forecasts for nearly three decades. But now, AI has the potential to take the next step when it comes to predicting sun, rain, wind and snow by doing the work on its own, without using various models that human forecasters have relied on for generations. Hendrik Tolman, senior adviser for advanced modeling systems at the National Weather Service, told Fox News Digital this possibility is now on the horizon and is actively being explored.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. As the world of artificial intelligence continues to evolve, a New Jersey biotech company is taking AI capabilities to the next level. After decades of working with AI-driven phenotypic platforms in an attempt to develop drugs for mental illness, PsychoGenics has had a breakthrough with one compound that aims to treat schizophrenia. PsychoGenics president and CEO Emer Leahy spoke to Fox News Digital in a recent on-camera interview, explaining that she and her team are closer than ever to developing what she said is the first-ever AI-discovered drug.